| |
Present study |
Rastkari et al. [18] |
| Parameter |
25 mg Test* Formulation |
25 mg Reference† Formulation |
50-mg Test Formulation |
50-mg Reference Formulation |
| Cmax, ng/mL |
235.21 ± 275.79 (89.40) |
228.28 ± 198.72 (86.25) |
668 (324) |
674 (296) |
| Tmax, h |
0.82 ± 0.68 (0.25) |
0.72 ± 0.39 (0.16) |
0.84 (0.27) |
0.75 (0.23) |
| AUC0–t, ng/mL·h |
329.25 ± 188.43 (81.55) |
315.87 ± 228.21 (85.98) |
1017.7 (583.4) |
1032.4 (544.3) |
| AUC0–∞, ng/mL·h |
337.43 ± 192.13 (82.64) |
323.90 ± 225.90 (86.16) |
1023.6 (590.6) |
1057.4 (551.3) |
| t1/2, h |
2.83 ± 1.14 (0.49) |
2.86 ± 1.20 (0.42) |
3.37 (0.95) |
3.24 (0.87) |
*Caporil (manufactured by Scanlab Sdn. Bhd., Batu Caves, Selangor, Malaysia).
†Trademark: Apo Capto (manufactured by Apotex Inc., Toronto, Canada). |
